title: [Body dysmorphic disorder].
abstract: Body dysmorphic disorder (BDD) is a relatively common disorder with a point prevalence of 0.7-2.4 %. BDD is characterized by the patient's excessive concern with an imagined or slight defect in physical appearance. BDD usually begins in adolescence. Comorbidity rates and also suicidality rates are high. The course of BDD tends to be chronic. According to the present state of knowledge, cognitive-behavioral therapy and pharmacotherapy with selective serotonin reuptake inhibitors are valuable options in the therapy of BDD. The case report describes a recent case of BDD with typical clinical and therapy-related characteristics. The aim of this work is to strengthen the awareness of BDD in clinical practice of child and adolescent psychiatry, facilitating an adequate diagnosis and treatment of the affected individuals.
authors.affiliation: Klinik für Kinder- und Jugendpsychiatrie/-psychotherapie, Universitätsklinikum Ulm.
authors.forename: Katharina
authors.initials: K
authors.lastname: Grau
authors.affiliation: Klinik für Kinder- und Jugendpsychiatrie/-psychotherapie, Universitätsklinikum Ulm.
authors.forename: Jörg Michael
authors.initials: JM
authors.lastname: Fegert
authors.affiliation: Klinik für Kinder- und Jugendpsychiatrie/-psychotherapie, Universitätsklinikum Ulm.
authors.forename: Marc
authors.initials: M
authors.lastname: Allroggen
mesh_terms: D000041:Absenteeism; D000293:Adolescent; D057215:Body Dysmorphic Disorders / Q000175:diagnosis* / Q000453:epidemiology / Q000523:psychology / Q000628:therapy; D002648:Child; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D015897:Comorbidity; D003430:Cross-Sectional Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010343:Patient Admission; D010698:Phobic Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000523:psychology / Q000628:therapy; D011743:Pyrimidines / Q000627:therapeutic use; D012307:Risk Factors; D059020:Suicidal Ideation
chemical_list: D011743:Pyrimidines; C001247:fluoxydine
keywords: Dysmorphophobie; Körperdysmorphe Störung; Pharmakotherapie; body dysmorphic disorder; cognitive-behavioral therapy; dysmorphophobia; kognitiv-behaviorale Therapie; pharmacotherapy